sacubitril hemicalcium salt

Sacubitril hemicalcium salt (AHU377 calcium salt) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696. Sacubitril hemicalcium salt is a prodrug of LBQ657, which is an inhibitor of the zinc metallopeptidase neprilysin. Neprilysin degrades a variety of vasoactive peptides such as atrial and brain natriuretic peptide, bradykinin, adrenomedullin, and endothelin-1. Inhibition of neprilysin leads to an increased level of these peptides and, thus, antihypertensive effects. Formulations containing AHU377 in combination with the angiotensin II receptor antagonist valsartan are used to treat hypertension and heart failure.

Sacubitril-13C4 hemicalcium salt is the carbon-13 and deuterium-labeled version of Sacubitril hemicalcium salt (T4200). Sacubitril (AHU-377) hemicalcium salt is a potent NEP inhibitor with an IC50 value of 5 nM. It is a component of the active pharmaceutical compound LCZ696, used in heart failure research.

Sacubitril-D4 hemicalcium salt is a deuterated form of Sacubitril hemicalcium salt (T4200). It is a potent NEP inhibitor with an IC50 of 5 nM.

Sacubitril-[D4] Hemicalcium Salt (Standard) is a reference standard of Sacubitril-[D4] Hemicalcium Salt intended for quantitative analysis, quality control, and related biochemical research applications.